1. Home
  2. PCRX vs CADL Comparison

PCRX vs CADL Comparison

Compare PCRX & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

N/A

Current Price

$24.59

Market Cap

949.9M

Sector

Health Care

ML Signal

N/A

Logo Candel Therapeutics Inc.

CADL

Candel Therapeutics Inc.

N/A

Current Price

$12.70

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PCRX
CADL
Founded
2006
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
949.9M
1.0B
IPO Year
2010
2021

Fundamental Metrics

Financial Performance
Metric
PCRX
CADL
Price
$24.59
$12.70
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
7
Target Price
$30.25
$19.00
AVG Volume (30 Days)
636.8K
1.3M
Earning Date
04-30-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
107.44
58.62
EPS
0.19
N/A
Revenue
$541,533,000.00
$125,000.00
Revenue This Year
$6.78
N/A
Revenue Next Year
$8.54
N/A
P/E Ratio
$129.84
N/A
Revenue Growth
26.04
N/A
52 Week Low
$18.80
$4.35
52 Week High
$27.66
$13.82

Technical Indicators

Market Signals
Indicator
PCRX
CADL
Relative Strength Index (RSI) 49.55 64.12
Support Level $24.61 $4.84
Resistance Level $25.06 N/A
Average True Range (ATR) 0.91 0.72
MACD -0.04 0.17
Stochastic Oscillator 47.59 65.54

Price Performance

Historical Comparison
PCRX
CADL

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About CADL Candel Therapeutics Inc.

Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Share on Social Networks: